PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Remarkably, many of these patients are highly responsive to checkpoint blockade treatment (Diaz and Le, 2015; Le et al., 2017; Le et al., 2015) where the tumor infiltrating CD8+ cytotoxic T cells can be reactivated by anti-PD1 antagonists to effectively eradicate tumors.”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Diaz and Le, 2015
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Epitope Landscape in Breast and Colorectal Cancer
Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416
Goldstein, J., Tran, B., Ensor, J., Gibbs, P., Wong, H. L., Wong, S. F., Vilar, E., Tie, J., Broaddus, R., Kopetz, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu100 · Cited by 288
Cited by
Items 401–435 of 435
Yang, H., Yu, M., Zhong, S., You, Y., & Feng, F. (2022) · Figshare · doi:10.6084/m9.figshare.19092525
Dang, Y., Yu, J., Zhao, S., Cao, X., & Wang, Q. (2022) · Figshare · doi:10.6084/m9.figshare.19204242
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346212
Satapathy, S. R., Ghatak, S., & Sjölander, A. (2023) · Figshare · doi:10.6084/m9.figshare.23520159
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346224
Wang, Z., Wang, X., Xu, Y., Li, J., Zhang, X., Peng, Z., Hu, Y., Zhao, X., Dong, K., Zhang, B., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19625616
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346218
Lu, Z., Chen, H., Jiao, X., Wang, Y., Wu, L., Sun, H., Li, S., Gong, J., Li, J., Zou, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16928616
Yang, H., Yu, M., Zhong, S., You, Y., & Feng, F. (2022) · Figshare · doi:10.6084/m9.figshare.19092522
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346209
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346215
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346221
Lu, Z., Chen, H., Jiao, X., Wang, Y., Wu, L., Sun, H., Li, S., Gong, J., Li, J., Zou, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16928619
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346227
Huang, Q., Wang, F., Zhang, X., Liu, J., Dou, X., Feng, R., 朱昆莉, Jiang, S., Zhang, Y., & Yue, J. (2024) · Figshare · doi:10.6084/m9.figshare.26604061
Trevisan, C. (2025) · Institutional Research Information System (University of Udine)
Immunotherapies in Biliary Tract Cancers: The Current Landscape
Yin, C., Alqhatani, A., & He, A. R. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_222
Recent advances in chemotherapy and targeted therapies for breast sarcoma
Dolcan, A., Ferraro, D. A., Tos, G. D., Cisarovsky, C., Wetterwald, L., Voutsadakis, I. A., Cherix, S., & Digklia, A. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2604619
Shahi, A., Zhao, S., & Kidane, D. (2026) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2025.15360
Diagnose und Therapieeinleitung bei chronischen und onkologischen Lungenerkrankungen
Grah, C. (2026) · Springer eBooks · doi:10.1007/978-3-662-71757-8_13
Sourrouille, I. (2019) · theses.fr (ABES) · doi:10.70675/71cd693dz253az49f0z8266zbfcd2387b7f8
Chen, J., Guan, H., Bai, Y., Guo, Y., Wang, X., & Wang, D. (2026) · Discover Oncology · doi:10.1007/s12672-026-04693-y
Setiono, S. B. V., Turalaki, G. L. A., & Tallei, T. E. (2026) · Heca Journal of Applied Sciences · doi:10.60084/hjas.v4i1.372
Advances in Neoadjuvant Therapy for Colorectal Cancer
练, 达. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1652038
Recent Advances in Cancer Treatment with PD-1/PD-L1 Inhibitors
Wang, X. (2026) · Journal of medicine and health science. · doi:10.62517/jmhs.202605106
Zhan, L.-Y., Zhe-ling, C., & Yang, L. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-025-01520-0
Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance
Zhang, J., Tufail, M., Deng, Y., Ling, H.-J., Peng, L., Wu, J., Zeng, D., Zhang, Y., He, L., Peng, H., et al. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101432
Yu, J. G., Xiao, X., He, W., Yang, Y., & Yue, J. (2026) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqag070
Hereditary Pancreatic Cancer: Genetic Risk, Surveillance Strategies, and Therapeutic Implications
Marafioti, M., Patruno, M., Musarra, M., Silvestris, N., Funes, J. A. P., Omero, F., Sapuppo, E., Cianci, V., Calabrò, M., Irrera, N., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146404 · Cited by 1
“The Food and Drug Administration has approved pembrolizumab for the treatment of unresectable or metastatic solid tumors with MSI-H or dMMR [212].”
Chen, Z., Zhong, Z., Liang, W., Feng, Q., 吴民耀, 林麗黛, Huang, G., Tang, X., Quan, J., Wei, J., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1675407
“PD-1 is an important immune checkpoint molecule, PD-L1 is one of the ligands of PD-1 (Ai et al., 2020; Dermani et al., 2019; Chen and Mellman, 2017), which can enhance the immune response to tumors and impairs the growth of cancer cells (Asaoka et al., 2015).”
An, Y., Yu, Z., Li, T., Li, X., & Jiang, Q. (2026) · Nanotechnology · doi:10.1088/1361-6528/ae9b13
Molecular events underlying sarcoma development and progression: the diagnostic relevance
Wiśniewska, A., Sobczuk, P., & Rutkowski, P. (2026) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2026.2733191
Allal, B.-E., Abdelaziz, I., Djerdjouri, B., & Bounaama, A. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109430
Lv, S., Ma, C., Tang, Z., Zhang, X., Shi, W., Zhang, S., Ni, M., Gu, L., & Chen, B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1969514
Tang, A. L., & Yao, H. (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.19958544
Metadata
- Authors
- Asaoka, Y., Ijichi, H., & Koike, K.
- ORCID
- Hideaki Ijichi
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-12
- Volume
- 373
- Issue
- 20
- Pages
- 1979-1979
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2597802455
- Cited by
- 426
- References
- 3
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 31 · 2023: 52 · 2022: 46 · 2021: 52 · 2020: 60 · 2019: 45 · 2018: 24 · 2017: 30 · 2016: 18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- anti-PD-1 therapy, mismatch repair deficiency, cancer immunotherapy, immune checkpoint inhibitors, microsatellite instability, Lynch syndrome, tumor immunology
- MeSH terms
- Antineoplastic Agents, Female, Humans, Male, Neoplasm Metastasis, DNA Mismatch Repair, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.